Blueprint ups Ayvakit guidance; Aurinia to advance autoimmune disease asset
Plus, news about Novo Holdings, Oxford Nanopore, Ionis, Valneva, LimmaTech and Bayer:
Blueprint pulls in $114.1 million for Ayvakit: The company
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
